These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 25085839

  • 1. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
    Wakasa T, Li Y, Bai Y, Liu Z, Ozaki T, Mori I, Miyauchi A, Kakudo K, Nakamura M.
    Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
    [Abstract] [Full Text] [Related]

  • 2. In papillary thyroid carcinoma BRAFV600E is associated with increased expression of the urokinase plasminogen activator and its cognate receptor, but not with disease-free interval.
    Ulisse S, Baldini E, Sorrenti S, Barollo S, Prinzi N, Catania A, Nesca A, Gnessi L, Pelizzo MR, Mian C, De Vito C, Calvanese A, Palermo S, Persechino S, De Antoni E, D'Armiento M.
    Clin Endocrinol (Oxf); 2012 Nov; 77(5):780-6. PubMed ID: 22702340
    [Abstract] [Full Text] [Related]

  • 3. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D, Hu S, Hou P, Jiang D, Condouris S, Xing M.
    Clin Cancer Res; 2007 Feb 15; 13(4):1341-9. PubMed ID: 17317846
    [Abstract] [Full Text] [Related]

  • 4. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M, Abbaszadegan MR, Bahar MM, Arabi A, Yadollahi M, Ghafari A, Taghehchian N, Zakavi SR.
    Endocr Res; 2014 Feb 15; 39(4):189-93. PubMed ID: 24679337
    [Abstract] [Full Text] [Related]

  • 5. ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V600E) mutation compared to that of corresponding normal thyroid tissues.
    Kim SW, Kim HK, Lee JI, Jang HW, Choe JH, Kim JH, Kim JS, Hur KY, Kim JH, Chung JH.
    Endocr Res; 2013 Feb 15; 38(2):89-97. PubMed ID: 23544999
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. BRAFV600E mutation, TIMP-1 upregulation, and NF-κB activation: closing the loop on the papillary thyroid cancer trilogy.
    Bommarito A, Richiusa P, Carissimi E, Pizzolanti G, Rodolico V, Zito G, Criscimanna A, Di Blasi F, Pitrone M, Zerilli M, Amato MC, Spinelli G, Carina V, Modica G, Latteri MA, Galluzzo A, Giordano C.
    Endocr Relat Cancer; 2011 Dec 15; 18(6):669-85. PubMed ID: 21903858
    [Abstract] [Full Text] [Related]

  • 8. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y, Liao D, Pan L, Ye R, Li X, Wang S, Ye C, Chen L.
    Eur J Endocrinol; 2013 May 15; 168(5):675-81. PubMed ID: 23416953
    [Abstract] [Full Text] [Related]

  • 9. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
    Zhang T, Shen X, Liu R, Zhu G, Bishop J, Xing M.
    Oncotarget; 2017 Jan 03; 8(1):900-914. PubMed ID: 27863429
    [Abstract] [Full Text] [Related]

  • 10. Increased CYP24A1 expression is associated with BRAF(V600E) mutation and advanced stages in papillary thyroid carcinoma.
    Zou M, BinHumaid FS, Alzahrani AS, Baitei EY, Al-Mohanna FA, Meyer BF, Shi Y.
    Clin Endocrinol (Oxf); 2014 Jul 03; 81(1):109-16. PubMed ID: 24382015
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Increased type 3 deiodinase expression in papillary thyroid carcinoma.
    Romitti M, Wajner SM, Zennig N, Goemann IM, Bueno AL, Meyer EL, Maia AL.
    Thyroid; 2012 Sep 03; 22(9):897-904. PubMed ID: 22823995
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
    Guerra A, Zeppa P, Bifulco M, Vitale M.
    Thyroid; 2014 Feb 03; 24(2):254-9. PubMed ID: 23806056
    [Abstract] [Full Text] [Related]

  • 15. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma.
    Fisher KE, Jani JC, Fisher SB, Foulks C, Hill CE, Weber CJ, Cohen C, Sharma J.
    J Surg Res; 2013 Nov 03; 185(1):217-24. PubMed ID: 23746767
    [Abstract] [Full Text] [Related]

  • 16. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
    Lukas J, Drabek J, Dudesek B, Vazan P, Stranska J, Jancik S, Mackova M, Syrucek M, Lukas D, Duskova J, Dundr P, Hintnausova B, Jiskra J.
    Exp Clin Endocrinol Diabetes; 2014 May 03; 122(5):268-72. PubMed ID: 24839220
    [Abstract] [Full Text] [Related]

  • 17. Dual specificity phosphatase 6 as a predictor of invasiveness in papillary thyroid cancer.
    Lee JU, Huang S, Lee MH, Lee SE, Ryu MJ, Kim SJ, Kim YK, Kim SY, Joung KH, Kim JM, Shong M, Jo YS.
    Eur J Endocrinol; 2012 Jul 03; 167(1):93-101. PubMed ID: 22535643
    [Abstract] [Full Text] [Related]

  • 18. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP, Rieger EY, Sinha DK, Evers CV, Cote GJ, Cabanillas ME, Hofmann MC.
    Oncotarget; 2016 May 24; 7(21):30907-23. PubMed ID: 27127178
    [Abstract] [Full Text] [Related]

  • 19. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
    Henderson YC, Fredrick MJ, Clayman GL.
    Arch Otolaryngol Head Neck Surg; 2007 Aug 24; 133(8):810-5. PubMed ID: 17709622
    [Abstract] [Full Text] [Related]

  • 20. TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.
    Zou M, Baitei EY, Al-Rijjal RA, Parhar RS, Al-Mohanna FA, Kimura S, Pritchard C, Binessa HA, Alzahrani AS, Al-Khalaf HH, Hawwari A, Akhtar M, Assiri AM, Meyer BF, Shi Y.
    Oncogene; 2016 Apr 14; 35(15):1909-18. PubMed ID: 26477313
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.